Optical Neuroimaging and Cognition

Recruiting now

Conditions studied: Dementia With Lewy Bodies, Alzheimer Disease, Mild Cognitive Impairment

In brief

Dementia is associated with a variety of neurovascular and neurometabolic abnormalities. Traditional imaging techniques used to investigate such abnormalities, such as Positron Emission Tomography and functional Magnetic Resonance Imaging, are not always well tolerated, have expensive start up and running costs, and are limited with regards to the types of experiments that can be performed as they can be highly sensitive to movement, are noisy, and have physical restrictions. Near-infrared spectroscopy (NIRS) is a non-invasive neuroimaging technique which uses light in the near-infrared spectrum to detect relative changes in concentration of oxygenated and deoxygenated haemoglobin, and the oxidation state of Cytochrome C Oxidase. As such, NIRS can provide measures of brain oxygenation and metabolism. NIRS is less sensitive to movement, is well tolerated and has few contraindications. It is thus a promising candidate for use in clinics or in peoples' homes for monitoring dementia. In the present study, the investigators aim to use both dual-wavelength and broadband NIRS in a range of dementia subtypes, including Alzheimer's Disease and Dementia with Lewy Bodies, and severities, including Mild Cognitive Impairment, to identify how brain oxygenation and metabolism is altered in dementia and across various clinical subgroups. The investigators also aim to determine the relationship between brain oxygenation and metabolism in dementia, and use machine learning approaches to identify optical biomarkers for dementia.

Key facts

Study ID

NCT05460143

Run by

University of Cambridge

People needed

200

Starts

2023-05-01

Expected to finish

2025-09-01

Last updated by the study team

2025-04-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• A diagnosis of probable:
• Lewy Body Dementia
• Alzheimer's Disease
• Mild Cognitive Impairment (MCI-LB or MCI-AD) OR
• Cognitively normal for their education and age, with a MMSE score above 26 AND
• A good grasp of the English language
• An informant (either a carer or family member) who will be available throughout testing (only relevant if in a patient group)

You may not qualify if…

• Severe dementia
• Unable to participate
• A MMSE score below 12
• A condition which influences metabolism or haemodynamics
• Such as metabolic or respiratory disorders
• A significant mental illness
• Such as rheumatoid arthritis, systemic lupus erythematosus
• Oral steroid use
• A significant psychiatric disorder
• MCI due to other causes such as traumatic brain injury, vascular dementia, or fronto-temporal dementia
• A history of excessive drug or alcohol use
• Contraindications to MRI (only for patient groups undertaking the MRI scan: AD/MCI/DLB)
• Surgical implants e.g. pacemakers
• Obesity

Where it is running

• Univeristy of Cambridge — Cambridge, United Kingdom (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.